ライフサイエンスコーパス: underlying disease

1 from inflammation and/or progression of the underlying disease.

2 se-free state, whereas 3% succumbed to their underlying disease.

3 itical role of biomarkers for diagnosing the underlying disease.

4 ic for this cell type and independent of the underlying disease.

5 the continuation of medical treatment of the underlying disease.

6 merely reflect abnormalities induced by the underlying disease.

7 This characteristic was independent of the underlying disease.

8 trathecal IgG synthesis independently of the underlying disease.

9 an add substantially to the morbidity of the underlying disease.

10 ndings and outcomes according to the type of underlying disease.

11 pathophysiology and the regulatory networks underlying disease.

12 ontrol group (n = 115, 2007-2008) with equal underlying disease.

13 derstand and reveal the molecular mechanisms underlying disease.

14 utilizing language phenotype as a marker of underlying disease.

15 for the analysis of the molecular mechanisms underlying disease.

16 acy of these techniques for the detection of underlying disease.

17 tentially teratogenic medications and severe underlying disease.

18 -risk cohort were alive and cured from their underlying disease.

19 sus have been critical for understanding the underlying disease.

20 ospital admission, advancing age, and severe underlying disease.

21 omise of reducing lung damage related to the underlying disease.

22 biases appear to vary with the nature of the underlying disease.

23 ng of inquiry influence these assessments of underlying disease.

24 y distinct characteristics, depending on the underlying disease.

25 hich may be due to early death driven by the underlying disease.

26 ce of contaminating pathogens, endotoxin, or underlying disease.

27 fection or bleeding above the rate caused by underlying disease.

28 nd menopause (age >/=50 years) regardless of underlying disease.

29 nvolvement is the first manifestation of the underlying disease.

30 rofile for each PED subtype related to their underlying disease.

31 ting and medication use independent from the underlying disease.

32 Most associations were also dependent on the underlying disease.

33 llis is not a diagnosis, but it is a sign of underlying disease.

34 ow-up, including genetic testing, to exclude underlying disease.

35 ere low, and deaths resulted mostly from the underlying disease.

36 iratory tract infections in individuals with underlying diseases.

37 s 36% and it correlated with the severity of underlying diseases.

38 inal CDIs is associated with the severity of underlying diseases.

39 l, 1.4-4.3]) when adjusted for age, sex, and underlying diseases.

40 le who are most vulnerable because of age or underlying diseases.

41 ntibodies to GM-CSF or is secondary to other underlying diseases.

42 iomyopathy and the other with lung cancer as underlying diseases.

43 atory tract infections, and exacerbations of underlying disease; 0.2%-11.5% of hospitalized patients

44 Due to the broad spectrum of underlying diseases, a multidisciplinary approach is nec

45 Bone marrow histology reflects underlying disease activity in ET but many morphological

46 Survival was also analyzed by underlying disease-acute liver failure (ALF) and chronic

47 tion remain elusive, and genomic alterations underlying disease advancement have only been identified

48 Patient-related risk factors include underlying disease, age, gender, comedications, nutritio

49 ffects of stem cell transplant (SCT) status, underlying disease, age, sex, ethnicity, and antibody st

50 he context and to assess the severity of the underlying disease alone to predict survival time and qu

51 may reflect reverse causality, in which the underlying disease alters biomarker levels or shared phy

52 end point that is an accurate measure of the underlying disease and is not confounded by potential sy

53 Depending on the underlying disease and its associated initial CMV risk,

54 Depending on the underlying disease and mechanisms, eosinophil infiltrati

55 is in some part due to the treatment of the underlying disease and not related to the iron supplemen

56 subjects can be obtained by identifying the underlying disease and oxygenation index on conventional

57 ed these pQTLs to study molecular mechanisms underlying disease and physiological phenotypes.

58 This risk varies with the nature of the underlying disease and seems to be greatest for membrano

59 he main reasons for a breakthrough event are underlying disease and subtherapeutic drug levels.

60 that could be mistaken for recurrence of the underlying disease and/or unrelated arteriosclerotic vas

61 in unselected patients with a broad range of underlying diseases and conditions has not been studied.

62 or unselected patients with a broad range of underlying diseases and conditions.

63 last year, both in the understanding of the underlying diseases and in improvements in the managemen

64 ibrosis develops as a consequence of various underlying diseases and presents a major diagnostically

65 Age, underlying disease, and HSCT type were significantly ass

66 e condition was interpreted to be due to the underlying disease, and immunosuppressive therapy was sc

67 well as factors specific to the patient, the underlying disease, and its treatment.

68 t itself, to its mode of administration, the underlying disease, and patient characteristics.

69 e tailored on the basis of disease severity, underlying disease, and prior therapies.

70 e for young children, three for persons with underlying disease, and two for pregnant women.

71 Patients were stratified for age, sex, and underlying diseases, and bacteria were identified by 16S

72 es, illuminating the molecular heterogeneity underlying diseases, and identifying new targets for the

73 rmal aging, decreased mobility, medications, underlying diseases, and rectal sensory-motor dysfunctio

74 in vivo and to identify molecular mechanisms underlying disease as a result of its mutation.

75 rhythms as a result of the severity of their underlying diseases as well as the intensive care unit e

76 of ventricular arrhythmias because of their underlying disease, as well as the placement and positio

77 l outcomes and risk of NV are related to the underlying disease associated with AVLs.

78 raction and have implications for mechanisms underlying disease associations of DQ2.

79 g systems-level analyses to reveal processes underlying disease associations.

80 e clustered into 7 different groups based on underlying disease (asthma, nasal polyps or chronic rhin

81 oing to reveal susceptibility loci for their underlying disease-atherosclerotic disease-identificatio

82 Underlying disease, baseline liver impairment, and conco

83 With the goal of downstaging underlying disease before alloSCT, AZA alone led to outc

84 ng is allowing for a better understanding of underlying disease biology, improved diagnostic accuracy

85 Assuming that the underlying disease burden was stable, only 30 of the 162

86 With the assumption of a constant underlying disease burden, only 8 of the 122 additional

87 When compared to those with the same underlying disease but not exposed to glucocorticoids, t

88 cus on treating the symptoms rather than the underlying disease cause.

89 While the mechanisms underlying disease caused by asymptomatic infections are

90 pts in beta-cell function could identify the underlying disease-causing genes, but large-scale studie

91 However, the underlying disease-causing mechanism remains uncertain.

92 s, and cell replacement therapy provided the underlying disease-causing mutation can be corrected.

93 es using patient-specific iPSCs, even if the underlying disease-causing mutation is not expressed in

94 Because of high age and multiple underlying diseases, CDI-related mortality is difficult

95 is is partly determined by the nature of the underlying disease, comorbidities and other immunosuppre

96 cause altered EV composition may reflect the underlying disease condition, circulating EVs can be exp

97 Clinical variables, including underlying disease, conditioning regimen, stem cell dono

98 ty, temporal patterns, network structure and underlying disease connections between EA, AA and HL pop

99 ontrol with corticosteroids or radiotherapy, underlying disease continued in 71% of patients and led

100 Analysis of vascular risk factors and underlying diseases detected by questionnaire and standa

101 The mechanisms underlying disease development and progression are await

102 r understanding of the molecular alterations underlying disease development and progression.

103 e adding to our understanding of the biology underlying disease development and progression.

104 Underlying disease diagnosis (lymphoid > myeloid) and re

105 This proinflammatory response may exacerbate underlying disease during P. aeruginosa infections.

106 nd further understand the genetic mechanisms underlying disease dynamics.

107 ardiac pacing, or treatments targeted at the underlying disease (e.g., acute coronary occlusion).

108 ical variables are often confounded with the underlying disease effects, which further hampers accura

109 Despite this, the mechanisms underlying disease emergence are still not fully underst

110 rological, and/or parasitological parameters underlying disease exacerbation in HIV-malaria coinfecte

111 could allow us to identify specific pathways underlying disease; explain disease heterogeneity by gro

112 terplay of genetic and environmental factors underlying disease expression.

113 laboratory parameters including age, gender, underlying disease, family history of cirrhosis or hepat

114 to be the most likely cause of death with no underlying disease found.

115 its frequency after specific techniques and underlying disease (four questions), its clinical conseq

116 wise type I error rate and power, depends on underlying disease-gene-environment associations, estima

117 < 0.001); however, after allogeneic SCT, the underlying diseases had little effect, except for multip

118 han in men (0.50% of 4,161) (P < 0.001), and underlying diseases had no effect in women.

119 se paraclinical tests aid in identifying the underlying disease has relevance to the practising clini

120 Whereas the detailed mechanisms underlying disease have yet to be fully elucidated, rece

121 st registration for liver transplantation by underlying disease (HBV and HCV infection and other) and

122 germline NF1 gene mutation may be one factor underlying disease heterogeneity.

123 the TMA, with the treatment directed at the underlying disease if possible.

124 ty, ostensibly caused by the severity of the underlying disease in many patients.

125 mortality, adjusted for the severity of the underlying disease, in patients with GI bleeding.

126 Underlying disease included mostly malignancies (n = 296

127 model to demonstrate that the progression of underlying disease increases the incidence, severity, an

128 nsidered to result from the pathology of the underlying disease, increasing evidence now indicates th

129 riptomic approach for identifying mechanisms underlying disease initiation and progression.

130 entify homogeneous subsets of patients whose underlying disease is driven by a specific mechanism tha

131 mortality independent of the severity of the underlying disease is unclear.

132 Many underlying diseases, like myelodysplastic syndrome (MDS)

133 duals (5 males and 5 females) and mapped the underlying disease locus to chromosome 16p12-p13 (LOD sc

134 Despite extreme underlying disease, long-term survival is excellent in p

135 bservation of patients for evidence that the underlying disease may complicate their pulmonary status

136 Physician monitoring of the infection and underlying diseases may not be as frequent despite the n

137 ects in animal models of RP depending on the underlying disease mechanism and that both effects are d

138 impaired lysosomal trafficking of PSAP is an underlying disease mechanism for NCL and FTLD due to GRN

139 However, the underlying disease mechanism in EFEMP2 mutations has not

140 4 may represent physical determinants of the underlying disease mechanism in inherited focal segmenta

141 The underlying disease mechanism in TTS is still unknown.

142 n made, a comprehensive understanding of the underlying disease mechanism is still lacking.

143 cle cells and TDP-43 loss-of-function as one underlying disease mechanism.

144 rchers face the challenge of deciphering the underlying disease mechanism.

145 distinct class of patients with a different underlying disease mechanism.

146 pharmacokinetic; 2) pharmacodynamic; and 3) underlying disease mechanism.

147 for providing probabilistic estimates of the underlying disease mechanism.

148 h there are few therapeutics that affect the underlying disease mechanism.

149 dies typically exclude these patients, their underlying disease mechanisms and appropriate treatment

150 onal profiling of ARDS blood PMNs to explore underlying disease mechanisms and identify therapeutic t

151 However, our insight into the underlying disease mechanisms and the development of nov

152 research is to identify the driving pathways underlying disease mechanisms and the heterogeneity of c

153 , has hampered our ability to understand the underlying disease mechanisms and to develop new therapi

154 n diseases is essential to understanding the underlying disease mechanisms and to developing therapeu

155 ssion profile of that cell type to elucidate underlying disease mechanisms and to identify novel targ

156 Although underlying disease mechanisms are not well understood, m

157 The underlying disease mechanisms are unclear, which complic

158 The underlying disease mechanisms are unclear; therefore, tr

159 disease are important for the exploration of underlying disease mechanisms as well as for testing nov

160 ven within the normal range, consistent with underlying disease mechanisms differing across CVDs.

161 t delineation of clinical phenotypes and the underlying disease mechanisms might help guide diagnosti

162 trophic lateral sclerosis (ALS) that reflect underlying disease mechanisms might help in diagnosis, s

163 genetic variation have been documented, the underlying disease mechanisms remain poorly elucidated.

164 Although the underlying disease mechanisms remain unknown, glial cell

165 A critical reappraisal of the underlying disease mechanisms, in particular the dynamic

166 six novel clinicopathobiological clusters of underlying disease mechanisms, with elevated mast cell m

167 el clusters that are associated with diverse underlying disease mechanisms, with increased mast cell

168 condition in terms of symptoms, course, and underlying disease mechanisms.

169 AR) with the aim of better understanding the underlying disease mechanisms.

170 s understanding the roles of microbes in the underlying disease mechanisms.

171 tic patients might provide new insights into underlying disease mechanisms.

172 e routine toxicity testing and evaluation of underlying disease mechanisms.

173 h performance characteristics independent of underlying disease mechanisms.

174 ic information with limited clarification of underlying disease mechanisms.

175 gy of the disease and tools for studying the underlying disease mechanisms.

176 n compounds to uncover important clues about underlying disease mechanisms.

177 ations have provided great insights into the underlying disease mechanisms.

178 arning a weight that better approximates the underlying disease model in a data-adaptive manner.

179 nd, in addition, allows investigation of the underlying disease models, including interactions.

180 Recent discoveries have identified underlying disease-modifying molecular aberrations contr

181 Here, we contrast the underlying disease networks and pathological mechanisms

182 intestinal in nature and consistent with the underlying disease; no unexpected adverse reactions were

183 thic MCAS, where neither an allergy or other underlying disease, nor KIT-mutated mast cells are detec

184 mpression therapy, although exacerbations of underlying disease occurred in the first 6 months of tre

185 e events in period 1 (excluding worsening of underlying disease) occurred in 1.3% of patients receivi

186 JAK-STAT signaling is part of the mechanism underlying disease onset and progression in dyW-/- mice.

187 Although the genetic determinants underlying disease onset remain unclear, epigenetic modi

188 ria and treatment strategies tailored to the underlying disease or genetic context are needed and wil

189 For patients in whom no underlying disease or hypereosinophilic syndrome is foun

190 patients were not withdrawn due to return of underlying disease or rejection episodes.

191 y to atherosclerosis development or reflects underlying disease or risk factors remains unclear.

192 In rats, this effect is independent of underlying disease or tissue injury.

193 95% CI, 1.4-20.9; P = .016), a rapidly fatal underlying disease (OR 4.4; 95% CI, 1.5-12.6; P = .006),

194 xin might be the principal virulence factors underlying disease organotropism.

195 ods for defining and staging the most likely underlying disease (osteoarthritis), clinically practica

196 to patient characteristics: age (P = 0.78), underlying disease (P = 0.30) and type of type of LTx (P

197 We show that underlying disease parameters cannot be inferred with co

198 t the most profound loss, but the mechanisms underlying disease pathogenesis are not fully understood

199 The mechanisms underlying disease pathogenesis are unclear, and there i

200 ent of SARS, a thorough understanding of the underlying disease pathogenesis has been hampered by the

201 e, we review the virology of EBV, mechanisms underlying disease pathogenesis in PIDs, and development

202 e latency, onset and progression, mechanisms underlying disease pathogenesis, and responses to new an

203 ty for investigating the cellular mechanisms underlying disease pathogenesis, evaluating potential th

204 athology and which reveals novel features of underlying disease pathogenesis.

205 rkinje cell dendritic morphology potentially underlying disease pathogenesis.

206 ion of the cellular and molecular mechanisms underlying disease pathogenesis.

207 expand our knowledge of evolutionary forces underlying disease pathogenesis.

208 ature and summarize the molecular mechanisms underlying disease pathology and examine their potential

209 ther these variants are risk factors for the underlying disease pathology, including neuritic plaques

210 ich has largely defied mapping analysis, the underlying disease pathology, undamped neuronal signalin

211 Our findings suggest possible differences in underlying disease pathophysiology and challenges to ide

212 Whether exenatide affects the underlying disease pathophysiology or simply induces lon

213 us pointing to common inflammatory processes underlying disease pathophysiology.

214 cal laboratory to identify sequence variants underlying disease phenotypes in patients.

215 ights into the genes and regulatory pathways underlying disease phenotypes.

216 portunity for identifying genes and pathways underlying disease phenotypes.

217 The association could be driven by underlying disease physiology or medications used to tre

218 than others, depending on the nature of the underlying disease physiology.

219 Geographic factors underlying diseased populations coupled with complementa

220 l require continued research into mechanisms underlying disease prevention, pathogenesis, progression

221 in which the drive for sleep exists but the underlying disease prevents its full expression.

222 use can be tailored to individual patients' underlying disease process and need for neuroprotective

223 invites speculation that they may mediate an underlying disease process in NDDs, which in turn may be

224 The underlying disease process is the major determinant of o

225 We identified biomarkers relevant to the underlying disease process progression and response to t

226 trate on novel and safe ways to modulate the underlying disease process rather than stopping excess t

227 with DME, suggesting that regardless of the underlying disease process, high levels of VEGF can caus

228 branous nephropathy and thus suggest another underlying disease process, such as combined membranous

229 opathy may not always accurately reflect the underlying disease process.

230 HCM and DCM, noncontrast T1 mapping detects underlying disease processes beyond those assessed by LG

231 LE) and further to get new insights into the underlying disease processes for better clinical managem

232 iance was strongest in SZ, suggesting common underlying disease processes jointly affecting the cereb

233 horn sheep populations to gain insights into underlying disease processes.

234 may slow cognitive decline but do not alter underlying disease processes.

235 omen and in other patients that have chronic underlying disease processes.

236 ion and act as surrogate markers to identify underlying disease processes.

237 ntial to illuminate the molecular mechanisms underlying disease progression and response to treatment

238 y be readily adapted to study the mechanisms underlying disease progression on all mucosal epithelia,

239 cially in progressive MS, thereby reflecting underlying disease progression.

240 offer new insights into the molecular events underlying disease progression.

241 ian cancer, potentially affecting many genes underlying disease progression.

242 pid mediators of inflammation and resolution underlying disease progression.

243 t this resonance may be a critical principle underlying disease propagation, with specific autoantige

244 The Pramipexole On Underlying Disease (PROUD) study was designed to identif

245 Management of the underlying disease, recognizing and preventing disease p

246 s to identify neural circuits and mechanisms underlying disease-relevant phenotypes.

247 However, isolating the minority of variants underlying disease remains an important, yet formidable

248 on, in association with the treatment of the underlying disease, represents a valid approach that can

249 o investigate the complex signaling networks underlying disease resistance in Arabidopsis.

250 Characterization of the genetic components underlying disease resistance is a major research area i

251 In all cases, the underlying disease responded well to rituximab.

252 Management of the underlying disease resulted in long-term remission of th

253 rough the investigation of individual traits underlying disease risk.

254 k to sex-specific neurodevelopmental changes underlying disease risk.

255 However, mechanisms underlying disease severity and virulence in arenavirus

256 Although underlying disease severity could also play a role, avoi

257 Physician appraisal of underlying disease severity is potentially vulnerable to

258 sis of this virus and investigate mechanisms underlying disease severity variation in the absence of

259 icult to establish because of confounding by underlying diseases, severity of infection, and differen

260 actors for P. aeruginosa infections, whereas underlying disease, source of infection, and severity of

261 However, because the underlying disease-specific pruritogens and itch-specifi

262 he indication for their removal has not been underlying disease states in those organs.

263 Underlying disease states such as cardiovascular disease

264 ophin signaling may play a role in processes underlying disease states such as schizophrenia, Alzheim

265 l annotation (E) including genetic defect or underlying disease/substrate, and the functional status

266 the retina may sustain injury as a result of underlying disease such as diabetes, and/or the interact

267 nsion (PH), whether idiopathic or related to underlying diseases such as HIV infection, results from

268 in may contribute to metabolic dysregulation underlying diseases, such as obesity and type 2 diabetes

269 al posterior medial temporal lobe due to the underlying disease, suggesting that it is the capacity o

270 ndings provide a novel molecular explanation underlying disease susceptibility associated with COX-2

271 ls experiencing a shocking incident, but the underlying disease susceptibility gene networks remain p

272 t, for the majority of these, the mechanisms underlying disease susceptibility remain unknown.

273 nt data defining the common genetic variants underlying disease susceptibility, and explore how impro

274 ication and description of genetic variation underlying disease susceptibility, efficacy, and adverse

275 (GWAS) in PD have identified common variants underlying disease susceptibility, while gene expression

276 de the identification of regulatory variants underlying disease susceptibility.

277 ular events for decades, suggesting that the underlying disease that caused stroke at a young age con

278 The most common underlying disease that results in recurrence on treatme

279 impact on the clinical presentation and the underlying disease that triggers cryoglobulin formation.

280 but it can also identify pathogenic variants underlying diseases that are not being sought (secondary

281 Independently of the underlying disease, the development of pulmonary hyperte

282 hese findings suggest that regardless of the underlying disease, the presence of CXCR4(+)/IgG(+) PCs

283 need to take into account the nature of the underlying disease, the severity of the nephrotic syndro

284 s often provide estimates of the severity of underlying disease to aid patients and families when for

285 neutropenia as the sole abnormality, with no underlying disease to which the neutropenia can be attri

286 Success in reconstructing gene networks underlying disease traits (or other complex traits like

287 prioritize and biologically interpret genes underlying disease traits of interest.

288 munities has made identifying the mechanisms underlying disease transmission and progression extremel

289 ssociated with the neuropathological effects underlying disease-, trauma- and chemically induced neur

290 ndiagnosed chronic kidney disease (CKD) from underlying disease, treatment, or both.

291 use, whereas univariate analysis identified underlying disease, type of operation, and high levels o

292 Overall, chronic underlying disease was found in 71% of patients, among w

293 rocognition from the effects inherent to the underlying disease, we analysed the results from randomi

294 The main underlying diseases were acute leukemia (35.7%), lymphom

295 Underlying diseases were present in 91 (59.9%) patients;

296 rted series, but bleeding manifestations and underlying diseases were similar.

297 Major underlying diseases were solid organ transplantation (24

298 The underlying diseases were Stevens-Johnson syndrome (22 ey

299 In these patients, treatment of the underlying disease will also increase platelet counts.

300 loss contributes to the functional deficits underlying diseases with a demyelinating component.